Impact of Safety-Related Regulatory Action on Clinical Practice
Tóm tắt
Background: After market approval, new serious safety issues are regularly identified for drugs that lead to regulatory action to inform healthcare professionals. However, the effectiveness of these safety-related regulatory actions is under question. We currently lack a comprehensive overview of the effects of these drug safety warnings on clinical practice to resolve the debate about their effectiveness.
Objective: The aim of this systematic review is to provide an overview of studies that assessed the impact of safety warnings.
Study Selection: A systematic search was performed for articles assessing the impact of Direct Healthcare Professional Communications or ‘Dear Doctor’ letters, Black Box Warnings and Public Health Advisories on clinical behaviour published between January 1996 and January 2010. The following variables were extracted: publication year, country, name of the drug, safety issue, specific safety warning (Direct Healthcare Professional Communication/Black Box Warning/Public Health Advisory), effect (intended/unintended) of the safety warning, outcome measure and study design. Papers were checked for several quality aspects. Study data were summarized using descriptive analyses.
Results: A total of 50 articles were identified. Two articles assessed two different drugs and were therefore counted twice (n = 52). Thirty-three articles described the impact of safety warnings issued for three drugs and drug groups, i.e. third-generation oral contraceptives, cisapride and selective serotonin reuptake inhibitors. The remaining 19 articles described a broad variety of 14 drugs and drug groups. Twenty-five studies applied an interrupted time series design, 23 a controlled or uncontrolled before/after design, and four articles applied both. None of the articles could rule out the influence of confounding factors. The intended effects were reported in 18 (72%) of the 25 before/after analyses, whereas only 11 (41%) of the 27 interrupted time series analyses reported an impact. Only two (8%) of the before/after analyses against 11 (41%) of the interrupted time series analyses reported mixed impacts. When unintended effects were assessed in case of selective serotonin reuptake inhibitors and third-generation oral contraceptives, these were almost always present: in 19 of 22 and 4 of 5 articles, respectively. Our review shows that safety-related regulatory action can have some impact on clinical practice but firm conclusions are difficult to draw. Evidence is primarily based on three drugs and drug groups. Almost half of the studies had inadequate before/after designs and the heterogeneity in analyses and outcome measures hampered the reporting of overall effect sizes. Studies with adequate interrupted time series design reported a more mixed impact of safety warnings than before/after studies. Furthermore, this review shows the relevance of considering not only the intended but also the unintended effects of safety warnings.
Conclusions: There is a clear need for further research with appropriate study designs and statistical analyses, with more attention to confounding factors such as media coverage, to understand the impact of safety-related regulatory action.
Tài liệu tham khảo
Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf 2007; 16(1): 5–16
Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 07; 329(7456): 44–7
Mol PGM, Straus SMJM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf 2010; 33(6): 463–74
Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 05; 287(17): 2215–20
Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Saf 2010; 33(2): 127–37
Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52(4): 600–8
Graham DJ, Ouellet-Hellstrom R, Macurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglita-zone or pioglitazone. JAMA 2010 07; 304(4): 411–8
Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008 10; 300(16): 1887–96
Woosley RL. Drug labeling revisions: guaranteed to fail? JAMA 2000 12; 284(23): 3047–9
Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27(8): 519–34
Murray ML, Thompson M, Santosh PJ, et al. Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005; 28(12): 1151–7
Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164(9): 1356–63
Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidally with SSRIs. Am J Psychiatry 2007; 164(8): 1198–205
Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65(1): 94–101
Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008 03; 336(7643): 542–5
The European Parliament and the European Council. Regulation (EU) no. 1235/2010. 2010 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF [Accessed 2010 Jan 4]
The European Parliament and the European Council. Directive 2010/84/EU. 2010 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF [Accessed 2011 Jan 4]
Ramsay CR, Matowe L, Grilli R, et al. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care 2003; 19(4): 613–23
National Health Service Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for carrying out or commissioning reviews. 2nd ed. CRD Report 4. York: University of York, 2001
Cochrane Effective Practice and Organisation of Care Review Group. The data collection checklist [online]. Available from URL: http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf [Accessed 2011 Apr 13]
Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004; 24(8): 978–86
Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Managed Care Pharm 2008; 14(6): 523–31
Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12(4): 295–301
Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000 12; 284(23): 3036–9
Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001 10; 286(13): 1607–9
Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘Dear Doctor’ letters. Pharmacoepidemiol Drug Saf 2001; 10(3): 211–8
Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 2007; 161(7): 690–6
Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64(4): 466–72
Forrester MB. Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas. Public Health 2008; 122(12): 1356–62
Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008; 165(1): 42–50
Singh T, Prakash A, Rais T, et al. Decreased use of antide-pressants in youth after US Food and Drug Administration black box warning. Psychiatry (USA) 2009; 6(10): 30–4
Carlson AM, Stockwell Morris L. Coprescription of terfenadine and erythromycin or ketoconazole: an assessment of potential harm. J Am Pharm Assoc 1996; 36(4): 263–9
Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996 05; 275(17): 1339–41
Burkhart GA, Sevka MJ, Temple R, et al. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997; 61(1): 93–6
Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001 08; 286(7): 831–3
Cluxton Jr RJ, Li Z, Heaton PC, et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 2005; 14(1): 1–9
Shatin D, Gardner JS, Stergachis A, et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 2005; 14(3): 149–54
Shatin D, Rawson NSB, Curtis JR, et al. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf 2006; 15(1): 11–8
Willy ME, Manda Shatin D, et al. A study of compliance with FDA recommendations for pemoline (Cylert®). J Am Acad Child Adolesc Psychiatry 2002; 41(7): 785–90
Gleason PP, Walters C, Heaton AH, et al. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Managed Care Pharm 2007; 13(5): 420–5
Kazmierczak R, Coley Impact of ‘Dear Doctor’ letters on prescribing: evaluation of the use of tramadol HCl. Formulary 1997; 32(9): 968–78
Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164(6): 884–91
Child TJ, Mackenzie IZ, Rees M. Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare [letter]. BMJ 1996; 313(7063): 1005
Ferguson JJ, Jenkins MGV, Murty J, et al. Effect of CSM’s warning about safety of third generation oral contraceptives. BMJ 1996; 313(7053): 363–4
Martin RM, Hilton SR, Kerry SM. The impact of the October 1995 ‘pill scare’ on oral contraceptive use in the United Kingdom: analysis of a general practice automated database. Fam Pract 1997; 14(4): 279–84
Roberts SJ. The immediate effects of the pill safety scare on usage of combined oral contraceptives in north east England. J Epidemiol Community Health 1997; 51(3): 332–3
Wood R, Botting B, Dunnell K. Trends in conceptions before and after the 1995 pill scare. Popul Trends 1997; (89): 5–12
Farmer RDT, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000 08; 321(7259): 477–9
Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997; 55(1): 11–4
Williams D, Kelly A, Carvalho M, et al. Effect of the British warning on contraceptive use in the General Medical Service in Ireland. Ir Med J 1998; 91(6): 202–3
De Vries CS, Van Den Berg PB, De Jong-Van Den Berg LTW. Oral contraceptive use before and after the latest pill scare in the Netherlands: changes in oral contraceptive use and how users change. Contraception 1998; 57(4): 247–9
Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001 04; 285(14): 1840–1
Staniscia T, Romano F, Festi D, et al. Co-dispensing of contraindicated medications in patients using cisapride in Italy. Pharmacoepidemiol Drug Saf 2006 07; 15(7): 469–76
De Bruin ML, Panneman MJM, Leufkens HGM, et al. Use of cisapride with contraindicated drugs in the Netherlands. Ann Pharmacother 2002; 36(2): 338–43
Bergen H, Hawton K, Murphy E, et al. Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds. Br J Clin Pharmacol 2009; 68(4): 618–29
Wheeler BW, Metcalfe C, Gunnell D, et al. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol 2009; 68(5): 752–64
Malgarini RB, Pimpinella G. Thrombotic thrombocytopenic purpura induced by ticlopidine: the power of ‘Dear Health Professional’ letters. Ann Pharmacother 2000; 34(3): 404–5
Motola D, Vargiu A, Leone R, et al. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf 2008; 31(7): 609–16
Morera T, Gervasini G, Carrillo JA, et al. Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. Basic Clin Pharmacol Toxicol 2005; 96(4): 289–94
De la Porte M, Reith D, Tilyard M. Impact of safety alerts upon prescribing of cisapride to children in New Zealand. N Z Med J 2002; 115(1157): 1–9
Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178(8): 1005–11
Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 2007; 97(4): 750–4
Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents: changes in utilization after safety warnings. Pharmacoepidemiol Drug Saf 2007; 16(9): 1048–53
Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008 08; 179(5): 438–46
Azoulay L, Oraichi D, Berard A. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006 08; 62(8): 667–74
Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66(6): 633–9
Panorama. The secrets of seroxat. BBC News [online]. Available from URL: http://news.bbc.co.uk/2/hi/programmes/panorama/2310197.stm [Accessed 2011 Feb 10]
US Food and Drug Administration. Historical information on antidepressant use in children, adolescents, and adults [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096293.htm [Accessed 2011 Feb 15]
Berry DC, Raynor DK, Knapp P, et al. Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately. Contraception 2002 11; 66(5): 305–7
Ramsay C, Brown E, Hartman G, et al. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52(5): 764–71
Lu CY, Ross-Degnan D, Soumerai SB, et al. Interventions to improve the quality and efficiency of medication use in managed care: a critical review of the literature 2001–2007. BMC Health Serv Res 2008; 8: 75–86
Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27(4): 299–309